Scienture Holdings, Inc. added its flagship product, Arbli™ (losartan potassium oral suspension), to the formularies of key national payors, expanding coverage to more than 100 million insured lives across the United States.
Arbli™ is the first FDA‑approved ready‑to‑use liquid losartan in the U.S. market. The drug received FDA approval on March 18 2025 and has a 24‑month shelf life when stored at room temperature.
The U.S. losartan market is estimated at $256 million in annual sales, with over 71 million prescriptions written each year. Globally, the losartan market is valued at roughly $1.5 billion. Arbli™ addresses a critical unmet need for patients who cannot tolerate solid tablets by offering a convenient, pre‑measured liquid dosage.
Despite the positive formulary inclusion, Scienture’s financial performance remains weak. In Q2 2025 the company reported a net loss of $6.7 million on zero revenue, while Q2 2024 saw a net loss of $1.8 million on $18,699 in revenue. The company has an accumulated deficit, a low cash balance, and has disclosed substantial doubt about its ability to continue as a going concern.
Arbli™ is a key product for Scienture’s future revenue generation, and the company views the formulary additions as a critical step toward capturing market share. However, the company must manage its operating expenses and cash position carefully to sustain its commercialization efforts.
The addition of Arbli™ to major national health plan formularies represents a significant commercial milestone for Scienture, but the company’s ongoing financial challenges underscore the need for disciplined execution as it seeks to translate the product’s market potential into sustainable earnings.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.